CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Understanding the Etiology of Pancytopenias in the CAR T-Cell Therapy Setting: What We Know and What We Don't?
Understanding the Etiology of Pancytopenias in the CAR T-Cell Therapy Setting: What We Know and What We Don't?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞（CAR-T 细胞）疗法代表了一种创新且具有变革性的治疗方法，用于复发和/或难治性（R/R）血液系统恶性肿瘤患者。CAR-T 细胞疗法最初获批用于R/R弥漫性大B细胞淋巴瘤（DLBCL）和急性淋巴细胞白血病，如今CAR-T 细胞疗法的应用已扩展至多发性骨髓瘤及其他淋巴瘤亚型，如滤泡性淋巴瘤和套细胞淋巴瘤。目前也正在DLBCL的早期治疗线中进行探索。CAR-T 细胞疗法具有独特的毒性特征，CAR-T 细胞治疗后出现血细胞减少已在所有关键临床试验中被报道，目前被认为是相关副作用。在此，我们对CAR-T 细胞治疗后血细胞减少的病因、后果及当前管理策略进行了深入评估。
Chimeric antigen receptor T-cell (CAR T-cell) therapy represents an innovative and transformative therapy for patients with relapsed and/or refractory (R/R) hematological malignancies. CAR T-cell therapy was first approved in R/R diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia, today the use of CAR T-cell therapy has expanded to multiple myeloma and other lymphoma subtypes such as follicular and mantle cell lymphoma.
It is also being explored in earlier lines of therapy in DLBCL. CAR T-cell therapy is associated with a unique toxicity profile and development of cytopenias post CAR T-cell therapy has been reported in all pivotal clinical trials and is now considered a related side effect.
Here, we provide an in-depth evaluation of etiologies, consequences, and current management strategies for cytopenias following CAR T-cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
